Publication:
Branimycins B and C, Antibiotics Produced by the Abyssal Actinobacterium Pseudonocardia carboxydivorans M-227.

dc.contributor.authorBraña, Alfredo F
dc.contributor.authorSarmiento-Vizcaíno, Aida
dc.contributor.authorPérez-Victoria, Ignacio
dc.contributor.authorOtero, Luis
dc.contributor.authorFernández, Jonathan
dc.contributor.authorPalacios, Juan José
dc.contributor.authorMartín, Jesús
dc.contributor.authorde la Cruz, Mercedes
dc.contributor.authorDíaz, Caridad
dc.contributor.authorVicente, Francisca
dc.contributor.authorReyes, Fernando
dc.contributor.authorGarcía, Luis A
dc.contributor.authorBlanco, Gloria
dc.date.accessioned2023-01-25T09:43:22Z
dc.date.available2023-01-25T09:43:22Z
dc.date.issued2017-02-07
dc.description.abstractTwo new antibiotics, branimycins B (2) and C (3), were produced by fermentation of the abyssal actinobacterium Pseudonocardia carboxydivorans M-227, isolated from deep seawater of the Avilés submarine Canyon. Their structures were elucidated by HRMS and NMR analyses. These compounds exhibit antibacterial activities against a panel of Gram-positive bacteria, including Corynebacterium urealyticum, Clostridium perfringens, and Micrococcus luteus, and against the Gram-negative bacterium Neisseria meningitidis. Additionally, branimycin B displayed moderate antibacterial activity against other Gram-negative bacteria such as Bacteroides fragilis, Haemophilus influenzae, and Escherichia coli, and branimycin C against the Gram-positive Enterococcus faecalis and methicillin-sensitive and methicillin-resistant Staphylococcus aureus.
dc.identifier.doi10.1021/acs.jnatprod.6b01107
dc.identifier.essn1520-6025
dc.identifier.pmid28169531
dc.identifier.unpaywallURLhttps://digibuo.uniovi.es/dspace/bitstream/10651/42955/1/proofs%20branimycins%20B%20and%20C%20.pdf
dc.identifier.urihttp://hdl.handle.net/10668/10849
dc.issue.number2
dc.journal.titleJournal of natural products
dc.journal.titleabbreviationJ Nat Prod
dc.language.isoen
dc.organizationFundación MEDINA (Centro de Excelencia en Investigación de Medicamentos Innovadores en Andalucía)
dc.organizationFundación MEDINA
dc.page.number569-573
dc.pubmedtypeJournal Article
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 International
dc.rights.accessRightsopen access
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/
dc.subject.meshAnti-Bacterial Agents
dc.subject.meshEnterococcus faecalis
dc.subject.meshGram-Negative Bacteria
dc.subject.meshGram-Positive Bacteria
dc.subject.meshHaemophilus influenzae
dc.subject.meshMacrolides
dc.subject.meshMethicillin-Resistant Staphylococcus aureus
dc.subject.meshMicrobial Sensitivity Tests
dc.subject.meshMolecular Structure
dc.subject.meshNuclear Magnetic Resonance, Biomolecular
dc.titleBranimycins B and C, Antibiotics Produced by the Abyssal Actinobacterium Pseudonocardia carboxydivorans M-227.
dc.typeresearch article
dc.type.hasVersionSMUR
dc.volume.number80
dspace.entity.typePublication

Files